Sept. 8, 2025 — GE HealthCare recently announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado (flurpiridaz F18) injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.
Around 6 million myocardial perfusion imaging (MPI) procedures are performed each year in the U.S.1 Within that total, PET MPI represents roughly five to ten percent today2, and is increasingly used by U.S. cardiology practices.3 By strengthening delivery in office-based care, this collaboration is expected to accelerate adoption of Flyrcado, which in the Phase III AURORA trial demonstrated higher diagnostic efficacy versus SPECT MPI for detecting coronary artery disease.4
“This collaboration with CardioNavix is an important step in making Flyrcado available for patients nationwide, across all sites of care,” said Eric Ruedinger, vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics division for the U.S. and Canada. “CDL Nuclear Technologies is a trusted name in private cardiology and nuclear imaging, and today’s announcement underscores the confidence both organizations have in Flyrcado’s potential. This agreement helps establish the foundation needed to support GE HealthCare’s vision for Flyrcado’s growth in outpatient cardiac PET imaging and reinforces our commitment to innovation and patient-centered care.”
“We’re proud that CardioNavix will be the first distributor to bring Flyrcado to private practice cardiology,” said Lon Wilson, CEO of CDL Nuclear Technologies. “Through our nearly 225 customer sites, CDL and CardioNavix support around 220,000 patient procedures each year with end-to-end cardiac PET solutions—and that number continues to grow. Together with GE HealthCare, we’re helping more providers bring advanced cardiac PET to patients in both private office-based settings and hospitals.”
The DSA supports GE HealthCare’s long-term strategy to build the capabilities necessary for Flyrcado’s success in outpatient settings. Initial roll-out will begin in late 2025 and accelerate into broader expansion throughout 2026.
Go to www.gehealthcare.com for more information.
1. Miller, R. J. H., Bednarski, B. P., Pieszko, K., Kwiecinski, J., Williams, M. C., Shanbhag, A., Liang, J. X., Huang, C., Sharir, T., Hauser, M. T., Dorbala, S., Di Carli, M. F., Fish, M. B., Ruddy, T. D., Bateman, T. M., Einstein, A. J., Kaufmann, P. A., Miller, E. J., Sinusas, A. J., Acampa, W., Han, D., Dey, D., Berman, D. S., & Slomka, P. J. (2024). Clinical phenotypes among patients with normal cardiac perfusion using unsupervised learning: A retrospective observational study. EBioMedicine, 99, 104930. https://doi.org/10.1016/j.ebiom.2023.104930
2. GE HealthCare. (2024). Investor Day 2024 presentation: Pharmaceutical Diagnostics segment overview. Retrieved from https://investor.gehealthcare.com
3. Cardiovascular Business. (2024, September 12). Cardiac PET on the rise among U.S. cardiologists. Retrieved from https://cardiovascularbusiness.com
4. Maddahi, J., Orlandi, C., Packard, R. R. S., et al. (2023). Diagnostic performance of flurpiridaz F 18 PET myocardial perfusion imaging versus SPECT in the Phase III AURORA trial. Journal of the American College of Cardiology, 81(21), 2031–2044. https://doi.org/10.1016/j.jacc.2023.03.012
August 17, 2026 
